- Open Access
Schistosomiasis vaccine discovery using immunomics
© Driguez et al; licensee BioMed Central Ltd. 2010
- Received: 5 January 2010
- Accepted: 28 January 2010
- Published: 28 January 2010
The recent publication of the Schistosoma japonicum and S. mansoni genomes has expanded greatly the opportunities for post-genomic schistosomiasis vaccine research. Immunomics protein microarrays provide an excellent application of this new schistosome sequence information, having been utilised successfully for vaccine antigen discovery with a range of bacterial and viral pathogens, and malaria.
Accordingly, we have designed and manufactured a Schistosoma immunomics protein microarray as a vaccine discovery tool. The microarray protein selection combined previously published data and in silico screening of available sequences for potential immunogens based on protein location, homology to known protective antigens, and high specificity to schistosome species. Following cloning, selected sequences were expressed cell-free and contact-printed onto nitrocellulose microarrays. The reactivity of microarray proteins with antisera from schistosomiasis-exposed/resistant animals or human patients can be measured with labelled secondary antibodies and a laser microarray scanner; highly reactive proteins can be further assessed as putative vaccines. This highly innovative technology has the potential to transform vaccine research for schistosomiasis and other parasitic diseases of humans and animals.
- Protein Microarray
- Schistosoma Japonicum
- Schistosome Species
- Antigen Discovery
Schistosomiasis causes significant morbidity and mortality in the developing world with recent studies indicating that the geographic extent and burden of the disease exceeds official estimates . Praziquantel-based chemotherapy has achieved some success in controlling the disease but is not an optimal strategy due to its inadequate impact on reducing long-term transmission . Despite the mass chemotherapy programs, schistosome reinfection rates and prevalence continue to be unacceptably high, with rebound prevalence and morbidity an inevitable consequence if ongoing interventions are not sustained [2, 3]. Along with other options, long-term protection afforded by vaccination will be necessary for the future control and possible elimination of schistosomiasis. The currently available vaccine antigens were discovered empirically using attenuated schistosome larvae, protective monoclonal antibodies, or by analysis of human antibody and cytokine responses to recombinantly-derived proteins . These identified vaccine molecules may, however, lack the required efficacy because: 1) the vaccine-induced protective immunity generated in animal models may not translate to humans; 2) there is uncertainty about the type of human response most appropriate for protective immunity; and 3) the antigens may not be expressed on the schistosome apical surface, and will not therefore be exposed to the host immune system [2, 4].
Key to the identification of new target vaccine molecules and high throughput antigen discovery are the recently published complete genomes of Schistosoma japonicum and S. mansoni[5, 6], and related post-genomic research on the schistosome proteome, transcriptome, glycome and immunome [7, 8]. The amalgamation of the information provided by these data sets, together with consideration of the host-parasite immune response in the field of immunomics, promises to result in more rapid and promising antigen discovery and the development of an effective vaccine for schistosomiasis [9–11].
Conventional proteomic studies on schistosomes identified proteins from male and female worms, different life-cycle stages, and parasite fractions and excretions that were separated by one or two dimensional (1/2D) gel electrophoresis (GE) and/or liquid chromatography followed by mass spectrometry (MS). Exposed proteins on the schistosome surface can be further characterised using biotinylated reagents, infection sera and/or by enzymatic stripping . For example, 71 sero-reactive adult S. haematobium worm antigens were identified using 2D GE of soluble parasite fractions, labelling with resistant human sera, and identification by MS .
However, due to the limitations of MS detection and protein extract preparation and separation, often only the most abundant cytosolic and possibly least immunologically meaningful proteins can be identified by this procedure [7, 12]. An immunomics protein microarray provides a convenient method that avoids some of the limitations inherent in other proteomic approaches but allows profiling of the host immune response to parasite antigens in a high throughput manner.
Since the first application of immunomics for vaccine discovery, antigens for ten microbial pathogens have now entered clinical or preclinical development . Immunomics-based approaches typically combine in silico genome screening followed by high throughput protein expression, and purification and immunological testing of selected proteins . The genome mining techniques include reverse vaccinology and epitope mapping, i.e. the prediction of potential virulence factors or secreted/surface proteins, and immunogenic T- or B-cell epitopes [9, 10, 14]. A further modification to the immunomics selection process is the incorporation of comparative or pan-genomics, and structural-genomics [9, 11].
This protein microarray technology platform has been now applied to over 30 pathogens including viruses, bacteria and protists (e.g. ). The approach allows efficient expression of putative antigens without many of the problems of conventional protein expression and purification. This is exemplified by Plasmodium falciparum where high throughput protein expression using bacteria, yeast, insect cells as well as the wheat germ cell-free system results in very low expression efficiency because of its rare codon usage and high A + T content. However, using a similar platform to the Schistosoma protein microarray described here, >93% expression efficiency was achieved for a similar proof-of-concept study of 250 P. falciparum proteins with 14 new potential vaccine targets being identified .
A comparison of the characteristics of immunomics protein microarrays with conventional proteomic approaches
Conventional Proteomic Approaches
Can be limited
Present, depending on methods
Low abundance proteins lost
Pathogen Protein Extraction
Not applicable (uses DNA/cDNA)
Membrane proteins difficult to extract and detect
Nevertheless, this antigen discovery approach will be readily adaptable to other parasites as more genome sequence information and post-genomic data become available. We anticipate that such microarray platforms will facilitate the identification of novel vaccine candidates that may not have been revealed using conventional methodologies, thereby providing a valuable approach for vaccine discovery.
Advantages and disadvantages of immunomics protein microarray technology.
Proteome-wide, selective expression of full-length proteins including insoluble and membrane proteins
Protein expression can be determined from C- and N-terminal tags
High throughput screening of antibody responses from experimentally immunized or naturally exposed individuals and animal models
Small serum sample volume (1 microliter) required for immunoscreening
Some loss of protein tertiary structure and post-translational modifications
Reactivity is not directly comparable between microarray antigens
Microarray protein levels cannot be quantified
Antibodies against E. coli proteins in cell-free extract must be blocked
We would like to thank the staff at the Protein Microarray laboratory, UCI and Antigen Discovery Incorporated (ADi) for training and assistance in the manufacture and use of the schistosome microarray and Fred Lewis (NIH-NIAID Schistosomiasis Resource Center) for providing sera from schistosome-infected mice. Funding was provided by the ARC/NHMRC Research Network for Parasitology (Australia), the NHMRC (Australia) and the Australian Centre for Vaccine Development.
- Bergquist R, Utzinger J, McManus DP: Trick or treat: the role of vaccines in integrated schistosomiasis control. PLoS Negl Trop Dis. 2008, 2: e244-10.1371/journal.pntd.0000244.PubMed CentralView ArticlePubMedGoogle Scholar
- McManus DP, Loukas A: Current status of vaccines for schistosomiasis. Clin Microbiol Rev. 2008, 21: 225-242. 10.1128/CMR.00046-07.PubMed CentralView ArticlePubMedGoogle Scholar
- Clements AC, Bosque-Oliva E, Sacko M, Landoure A, Dembele R, Traore M, Coulibaly G, Gabrielli AF, Fenwick A, Brooker S: A comparative study of the spatial distribution of schistosomiasis in mali in 1984-1989 and 2004-2006. PLoS Negl Trop Dis. 2009, 3: e431-10.1371/journal.pntd.0000431.PubMed CentralView ArticlePubMedGoogle Scholar
- Bergquist R, Al-Sherbiny M, Barakat R, Olds R: Blueprint for schistosomiasis vaccine development. Acta Trop. 2002, 82: 183-192. 10.1016/S0001-706X(02)00048-7.View ArticlePubMedGoogle Scholar
- Liu F, Zhou Y, Wang ZQ, Lu G, Zheng H, Brindley PJ, McManus DP, Blair D, Zhang QH, Zhong Y: The Schistosoma japonicum genome reveals features of host-parasite interplay. Nature. 2009, 460: 345-351. 10.1038/nature08202.PubMed CentralView ArticleGoogle Scholar
- Berriman M, Haas BJ, LoVerde PT, Wilson RA, Dillon GP, Cerqueira GC, Mashiyama ST, Al-Lazikani B, Andrade LF, Ashton PD: The genome of the blood fluke Schistosoma mansoni. Nature. 2009, 460: 352-358. 10.1038/nature08160.PubMed CentralView ArticlePubMedGoogle Scholar
- Wilson RA, Ashton PD, Braschi S, Dillon GP, Berriman M, Ivens A: 'Oming in on schistosomes: prospects and limitations for post-genomics. Trends Parasitol. 2007, 23: 14-20. 10.1016/j.pt.2006.10.002.View ArticlePubMedGoogle Scholar
- Hokke CH, Fitzpatrick JM, Hoffmann KF: Integrating transcriptome, proteome and glycome analyses of Schistosoma biology. Trends Parasitol. 2007, 23: 165-174. 10.1016/j.pt.2007.02.007.View ArticlePubMedGoogle Scholar
- Bambini S, Rappuoli R: The use of genomics in microbial vaccine development. Drug Discov Today. 2009, 14: 252-260. 10.1016/j.drudis.2008.12.007.View ArticlePubMedGoogle Scholar
- Davies MN, Flower DR: Harnessing bioinformatics to discover new vaccines. Drug Discov Today. 2007, 12: 389-395. 10.1016/j.drudis.2007.03.010.View ArticlePubMedGoogle Scholar
- Seib KL, Dougan G, Rappuoli R: The Key Role of Genomics in Modern Vaccine and Drug Design for Emerging Infectious Diseases. PLoS Genet. 2009, 5: e1000612-10.1371/journal.pgen.1000612.PubMed CentralView ArticlePubMedGoogle Scholar
- DeMarco R, Verjovski-Almeida S: Schistosomes--proteomics studies for potential novel vaccines and drug targets. Drug Discov Today. 2009, 14: 472-478. 10.1016/j.drudis.2009.01.011.View ArticlePubMedGoogle Scholar
- Mutapi F, Burchmore R, Mduluza T, Midzi N, Turner CM, Maizels RM: Age-related and infection intensity-related shifts in antibody recognition of defined protein antigens in a schistosome-exposed population. The Journal of infectious diseases. 2008, 198: 167-175. 10.1086/589511.View ArticlePubMedGoogle Scholar
- Scharnagl NC, Klade CS: Experimental discovery of T-cell epitopes: combining the best of classical and contemporary approaches. Expert Rev Vaccines. 2007, 6: 605-615. 10.1586/147605220.127.116.115.View ArticlePubMedGoogle Scholar
- Davies DH, Liang X, Hernandez JE, Randall A, Hirst S, Mu Y, Romero KM, Nguyen TT, Kalantari-Dehaghi M, Crotty S, Baldi P, Villarreal LP, Felgner PL: Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc Natl Acad Sci USA. 2005, 102: 547-552. 10.1073/pnas.0408782102.PubMed CentralView ArticlePubMedGoogle Scholar
- Molina DM, Pal S, Kayala MA, Teng A, Kim PJ, Baldi P, Felgner PL, Liang X, de la Maza LM: Identification of immunodominant antigens of Chlamydia trachomatis using proteome microarrays. Vaccine. 2009,Google Scholar
- Felgner PL, Kayala MA, Vigil A, Burk C, Nakajima-Sasaki R, Pablo J, Molina DM, Hirst S, Chew JS, Wang D, Tan G, Duffield M, Yang R, Neel J, Chantratita N, Bancroft G, Lertmemongkolchai G, Davies DH, Baldi P, Peacock S, Titball RW: A Burkholderia pseudomallei protein microarray reveals serodiagnostic and cross-reactive antigens. Proc Natl Acad Sci USA. 2009, 106: 13499-13504. 10.1073/pnas.0812080106.PubMed CentralView ArticlePubMedGoogle Scholar
- Doolan DL, Mu Y, Unal B, Sundaresh S, Hirst S, Valdez C, Randall A, Molina D, Liang X, Freilich DA, Oloo JA, Blair PL, Aguiar JC, Baldi P, Davies DH, Felgner PL: Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics. 2008, 8: 4680-4694. 10.1002/pmic.200800194.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.